Standarizing quality asssessment of observational studies for decision making in health care

Journal of Managed Care Pharmacy

Volumn 15, Issue 3, 2009, Pages 275-283

  Brixner, Diana I ^a   Holtorf, Anke Peggy ^a   Neumann, Peter J ^b   Malone, Daniel C ^c   Watkins, John B ^d  

^a UNIVERSITY OF UTAH   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG INDUSTRY; FUNDING; HEALTH CARE; MEDICAL RESEARCH; NOTE; OBSERVATIONAL STUDY; PHARMACEUTICAL CARE; QUALITY CONTROL; STANDARDIZATION; ECONOMICS; ETHICS; HEALTH INSURANCE; HEALTH SERVICES RESEARCH; HUMAN; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PEER REVIEW; PHARMACOECONOMICS; PUBLISHING; STANDARD;

DECISION MAKING, ORGANIZATIONAL; ECONOMICS, PHARMACEUTICAL; HEALTH SERVICES RESEARCH; HUMANS; MANAGED CARE PROGRAMS; PEER REVIEW; PUBLISHING; QUALITY CONTROL;

EID: 65449152879     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.3.275     Document Type: Note

References (49)

1. Holtorf A, Watkins JB, Mullins CD, Brixner D. Incorporating observational data into the formulary decision-making process - summary of a roundtable discussion. J Manag Care Pharm. 2008;14(3):302-08. Available at: www.amcp.org/data/jmcp/JMCPMaga_April08_302-308.pdf.
2. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326-35.
3. Anonymous. The AMCP Format for Formulary Submissions version 2.1. J Manag Care Pharm. 2005;11(5 Suppl B): vi-xvi, 1-29, 1-4. Available at: http://www.amcp.org/data/jmcp/formatsupp.pdf. Accessed February 15, 2009.
4. Anonymous. Business Wire: Research examines formulary decision process among health Plans. Business Wire. April 16, 2008. Available at: http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_16/ ai_n25156554/print. Accessed May 27, 2008.
5. Anonymous. Insights Into Formulary Decision Processes: Findings From A National Survey Of Health Plans. Presented to: The Foundation for Managed Care Pharmacy. Silver Spring, MD: Social & Scientific Systems, Inc.; March 2008. Available at: http://www.fmcpnet.org/cfr/ waSys/f.cfc?method=getListFile&id=3EE4422A. Accessed February 15, 2009.
6. Kilbourne AM, Neumann MS, Pincus HA, Bauer MS, Stall R. Implementing evidence-based interventions in health care: application of the replicating effective programs framework. Implement Sci. 2007;2(1):42. Available at: http://www.implementationscience.com/content/ 2/1/42. Accessed March 19, 2008.
7. Kitson AL, Rycroft-Malone J, Harvey G, McCormack B, Seers K, Titchen A. Evaluating the successful implementation of evidence into practice using the PARiHS framework: theoretical and practical challenges. Implement Sci. 2008;3(1):1. Available at: http://www.implementationscience.com/ content/3/1/1. Accessed March 19, 2008.
8. Elwyn G, Taubert M, Kowalczuk J. Sticky knowledge: A possible model for investigating implementation in healthcare contexts. Implement Sci. 2007;2(1):44. Available at: http://www.implementationscience.com/content/2/1/44. Accessed March 19, 2008.
9. Stetler CB, McQueen L, Demakis J, Mittman BS. An organizational framework and strategic implementation for system-level change to enhance research-based practice: QUERI Series. Implement Sci. 2008;3(1):30. Available at: http://www.implementationscience.com/content/ pdf/1748-5908-3-30.pdf. Accessed February 15, 2009.
10. ISPOR Using 'Real World' Data in Coverage and Reimbursement Decisions Task Force. Members' comments on draft report. Available at: http://www.ispor.org/workpaper/RWD_TF/MemberComments.pdf. Accessed June 6, 2008.
11. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. Available at: http://www.bmj.com/cgi/reprint_abr/328/7454/1490.pdf. Accessed February 15, 2009.
12. Atkins D, Briss PA, Eccles M, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res. 2005;5(1):25. Available at: http://www.biomedcentral.com/content/pdf/1472-6963-5-25.pdf. Accessed February 15, 2009.
13. Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106-10. Available at: http://www.bmj.com/cgi/reprint/336/7653/1106. Accessed February 15, 2009.
14. Tevaarwerk GJ. Grading evidence. CMAJ. 2004;170(6):928-29; author reply 929-30.
15. Upshur RE. Are all evidence-based practices alike? problems in the ranking of evidence. CMAJ. 2003;169(7):672-73.
16. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129(1):174-81.
17. Levels of Evidence. From the Centre for Evidence-based Medicine, Oxford. May, 2001. Available at: http://www.essentialevidenceplus.com/concept/ ebm_loe.cfm?show=oxford. Accessed March 2, 2009.
18. Agency for Healthcare Research and Quality. U.S. Preventive Services Task Force (USPSTF). Available at: http://www.ahrq.gov/clinic/ USpstfix.htm. Accessed February 8, 2009.
19. ACC/AHA Task Force on Practice Guidelines. Manual for ACC/AHA Guideline Writing Committees. 2004. Available at: http://www.acc.org/ qualityandscience/clinical/manual/manual%5Fiistep6.htm. Accessed February 8, 2009.
20. Rawlins M. De Testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372(9656):2152-61.
21. Department of Health. Drug treatment for multiple sclerosis (beta-interferons and glatiramer acetate) - risk-sharing scheme (HSC 2002/004 briefing note). January 12, 2004. Available at: http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycaretrusts/ DH_4000556. Accessed August 26, 2008.
22. Anonymous. Bortezomib Monotherapy for Relapsed Multiple Myeloma. Care Guideline. London, UK: National Institute for Health and Clinical Excellence; October 2007. Available at: http://www.nice.org.uk/nicemedia/ pdf/TA129Guidance.pdf. Accessed February 27, 2009.
23. Watkins J, Bresnahan B, Veenstra D, Garrison L, Sullivan S. Determining the value of diagnostic/genetic testing to inform health plan decision making: oncotype dx as a case study. Poster abstract. Value Health. 2007;10(3):A206.
24. Centers for Medicare & Medicaid Services. National coverage determinations with data collection as a condition of coverage: coverage with evidence development. July 12, 2006. Available at: https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8. Accessed August 18, 2008.
25. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood). 2006;25(5):1218-30.
26. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ: the BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275-83.
27. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-84.
28. Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361-66.
29. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health. 1998;1(2):131-47.
30. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health. 2007;10(5):336-47.
31. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003;6(2):90-97.
32. Peterson AM, Nau DP, Cramer JA, BennerJ, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
33. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):iii-iv, ix-xi, 1-158. Available at: http://www.hta.ac.uk/execsumm/summ836.htm. Accessed March 2, 2009.
34. von Elm E, Altman D, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Prev Med. 2007;45(4):247-51.
35. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9-17.
36. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53-61. Available at: http://www.amcp.org/data/jmcp/Formulary%20Management-53-61.pdf.
37. Hannover Consensus Group. [German recommendations for health care economic evaluation studies. revised version of the Hannover consensus. Hannover Consensus Group]. Med. Klin. (Munich). 2000;95(1):52-55.
38. Travail réalisé par les Membres du Collège des Économistes de la Santé. Guide méthodologique pour l'évaluation économique des stratégies de santé. July 2003. Available at: http://www.ces-asso.org/docs/ Guide_Methodologique_CES_2003.pdf. Accessed February 15, 2009.
39. Agency for Healthcare Research and Quality. Systems to Rate the Strength of Scientific Evidence. Summary, Evidence Report/Technology Assessment: Number 47. AHRQ Publication No. 02-E015, March 2002. Available at: http://www.ahrq.gov/clinic/epcsums/strengthsum.htm. Accessed February 2, 2009.
40. Fairman KA, Curtiss FR. Rethinking the "whodunnit" approach to assessing the quality of health care research - a call to focus on the evidence in evidence-based practice. J Manag Care Pharm. 2008;14(7):661-74. Available at: http://www.amcp.org/data/jmcp/ 661-674_FairmanCurtiss-Final.pdf.
41. McAlister FA, Fradette M, Graham M, et al. A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. Implement Sci. 2006;1(1):11. Available at: http://www.implementationscience.eom/content/ 1/1/11. Accessed March 19, 2008.
42. Grauer DW, Lee J, Odom TD, et al., eds. Pharmacoeconomics and Outcomes: Applications for Patient Care, Second Edition. Kansas City: American College of Clinical Pharmacy; 2003. Available for purchase at: http://www.accp.com/bookstore/peoc.aspx. Accessed February 27, 2009.
43. Kane-Gill S, Reddy P, Gupta SR, Bakst AW. Guidelines for pharmacoeconomic and outcomes research fellowship training programs: joint guidelines from the American College of Clinical Pharmacy and the International Society of [sic] Pharmacoeconomics and Outcomes Research. Pharmacotherapy. 2008;28(10):269e-76e. Available at: http://www.accp.com/docs/positions/guidelines/ PEORFellowshipGuidelines.pdf. Accessed February 27, 2009.
44. Graham ID, Tetroe J. Some theoretical underpinnings of knowledge translation. Acad Emerg Med. 2007;14(11):936-41.
45. Graham ID, Logan J, Harrison MB, et al. Lost in knowledge translation: time for a map? J Contin Educ Health Prof. 2006;26(1):13-24.
46. Lyles A. Standards and certification to recognize pharmacoeconomics as a profession. Clin Ther. 2003;25(3):1004-06.
47. Nichol MB, Knight TK, Epstein J, Honda DH, Tretiak R. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. J Manag Care Pharm. 2007;13(4):360-71. Available at: http://www.amcp.org/data/jmcp/ 360-71.pdf.
48. Spooner JJ, Gandhi PK, Connelly SB. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan. J Manag Care Pharm. 2007;13(1):37-43. Available at: http://amcp.org/data/jmcp/37-43.pdf.
49. About EQUATOR. Enhancing the QUAlity and Transparency Of health Research Network Website. Available at: http://www.equator-network.org/ index.aspx?o=1017. Accessed February 27, 2009.